Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 12 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-10.38 Insider Own1.06% Shs Outstand10.49M Perf Week2.20%
Market Cap428.52M Forward P/E- EPS next Y-5.12 Insider Trans- Shs Float10.38M Perf Month-13.23%
Income-44.60M PEG- EPS next Q-1.09 Inst Own54.92% Short Float4.58% Perf Quarter554.65%
Sales0.00M P/S- EPS this Y49.52% Inst Trans-80.99% Short Ratio0.50 Perf Half Y572.98%
Book/sh-1.56 P/B- EPS next Y1.63% ROA-94.31% Short Interest0.48M Perf Year398.17%
Cash/sh2.01 P/C20.31 EPS next 5Y- ROE-341.98% 52W Range3.03 - 49.87 Perf YTD576.32%
Dividend Est.- P/FCF- EPS past 5Y18.86% ROI- 52W High-18.09% Beta2.47
Dividend TTM- Quick Ratio0.74 Sales past 5Y76.56% Gross Margin- 52W Low1246.67% ATR (14)3.70
Dividend Ex-Date- Current Ratio0.74 EPS Y/Y TTM-2.35% Oper. Margin0.00% RSI (14)58.25 Volatility9.69% 9.37%
Employees19 Debt/Eq- Sales Y/Y TTM-100.00% Profit Margin- Recom1.00 Target Price55.00
Option/ShortYes / Yes LT Debt/Eq- EPS Q/Q30.47% Payout- Rel Volume0.30 Prev Close40.00
Sales Surprise- EPS Surprise16.01% Sales Q/Q- EarningsMar 12 BMO Avg Volume958.45K Price40.85
SMA204.65% SMA5022.70% SMA200207.28% Trades Volume291,657 Change2.12%
Date Action Analyst Rating Change Price Target Change
Mar-06-24Upgrade Jefferies Hold → Buy $4 → $46
Sep-08-20Downgrade ROTH Capital Buy → Neutral $40 → $3
Sep-08-20Downgrade RBC Capital Mkts Outperform → Sector Perform
Sep-08-20Downgrade Jefferies Buy → Hold $18 → $2.50
Sep-08-20Downgrade BTIG Research Buy → Neutral
Jul-07-20Initiated ROTH Capital Buy $40
Jun-17-20Initiated BTIG Research Buy $22
Mar-26-20Initiated Nomura Buy $12
Apr-05-19Initiated Jefferies Buy
Mar-20-19Initiated Oppenheimer Outperform $28
Apr-02-24 08:00AM
Mar-15-24 08:50AM
Mar-14-24 09:38AM
Mar-12-24 08:21AM
08:00AM Loading…
Mar-06-24 08:00AM
Feb-28-24 08:00AM
Feb-06-24 09:50AM
Feb-02-24 04:01PM
Jan-31-24 09:19AM
Jan-30-24 06:55PM
Jan-29-24 06:57AM
Jan-26-24 07:30AM
Jan-23-24 08:00AM
Jan-09-24 08:00AM
08:00AM Loading…
Dec-18-23 08:00AM
Dec-01-23 09:40AM
Nov-07-23 09:56AM
Nov-02-23 08:00AM
Oct-17-23 08:00AM
Oct-16-23 08:00AM
Oct-03-23 08:00AM
Sep-27-23 09:05AM
Sep-19-23 08:00AM
Aug-08-23 09:08AM
Jul-31-23 08:00AM
Jul-26-23 05:11PM
08:00AM Loading…
Jun-26-23 08:00AM
May-31-23 08:00AM
May-30-23 08:45PM
May-09-23 08:11AM
May-01-23 08:00AM
Apr-18-23 08:00AM
Apr-17-23 08:30AM
Mar-14-23 04:35PM
Mar-07-23 08:00AM
Mar-06-23 08:00AM
Mar-02-23 08:00AM
Feb-13-23 11:27AM
Nov-10-22 09:05AM
Nov-08-22 08:05AM
Nov-03-22 05:00PM
Oct-14-22 08:05AM
Sep-26-22 08:05AM
Sep-22-22 08:00AM
Sep-12-22 07:00AM
Aug-09-22 09:25AM
May-11-22 08:00AM
May-10-22 09:25AM
Apr-08-22 01:05PM
Mar-31-22 09:51AM
Mar-18-22 10:12AM
Mar-17-22 10:41AM
Mar-11-22 08:05AM
Mar-08-22 06:15PM
Mar-02-22 07:00AM
Jan-14-22 09:38AM
Jan-12-22 10:35AM
Dec-31-21 09:58AM
Dec-29-21 10:00AM
Dec-07-21 10:00AM
Nov-12-21 08:05AM
Nov-11-21 08:05AM
Nov-02-21 03:02PM
Oct-21-21 09:30AM
Sep-10-21 06:45AM
Aug-12-21 09:45AM
Jul-29-21 03:04PM
Jun-24-21 08:05AM
Jun-21-21 05:48PM
Jun-18-21 08:38AM
Jun-12-21 04:19AM
Jun-03-21 02:42AM
Jun-02-21 06:19AM
Jun-01-21 12:26PM
May-25-21 08:05AM
May-19-21 09:20AM
May-17-21 08:34AM
May-11-21 08:05AM
May-03-21 03:01PM
Apr-20-21 08:05AM
Mar-30-21 08:05AM
Mar-18-21 12:00PM
Mar-15-21 02:30PM
Mar-10-21 12:59AM
Mar-09-21 08:05AM
Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, which focuses on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its products include candidate, Lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. The company was founded in April 2009 and is headquartered in Norwood, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Moran Sean F.Chief Financial OfficerApr 10 '24Option Exercise30.001,78753,61048,605Apr 11 09:17 AM
Cormorant Asset Management, LP10% OwnerMar 08 '24Buy44.38300,00013,314,1932,025,000Mar 11 05:34 PM
Cormorant Asset Management, LP10% OwnerMar 07 '24Buy40.05250,00010,013,3671,725,000Mar 11 05:34 PM
Cormorant Asset Management, LP10% OwnerFeb 02 '24Buy19.00750,00014,250,0001,475,000Feb 06 04:00 PM
Cohen YuvalChief Executive OfficerJan 26 '24Option Exercise4.977,17935,6807,179Jan 30 04:56 PM
HOLMER ALAN FDirectorJan 26 '24Option Exercise4.976293,1261,379Jan 30 06:07 PM
Cormorant Asset Management, LP10% OwnerJan 26 '24Buy32.24282,6329,111,941725,000Jan 30 04:23 PM